See more : NuVista Energy Ltd. (NVA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alliance Nickel Limited (AXN.AX) Income Statement Analysis – Financial Results
- Champion Gaming Group Inc. (WGRFF) Income Statement Analysis – Financial Results
- Grupo Financiero Inbursa, S.A.B. de C.V. (4FY.F) Income Statement Analysis – Financial Results
- Pangolin Diamonds Corp. (KGHZF) Income Statement Analysis – Financial Results
- Eon Electric Limited (EON.NS) Income Statement Analysis – Financial Results
Monopar Therapeutics Inc. (MNPR)
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 15.44M | 280.36K | 101.49K |
| General & Administrative | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Selling & Marketing | -3.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.50M | 0.00 | 0.00 |
| Operating Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Cost & Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Interest Income | 429.04M | 21.24K | 24.02K | 81.90K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.22K | 48.26K | 7.23K | 0.00 |
| Depreciation & Amortization | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.33M | 2.10M | 1.19M | 688.56K |
| EBITDA | 429.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.55M | 8.03K | 1.25K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.40M | -16.60M | -1.19M | -688.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 429.04K | 21.24K | 24.02K | 204.30K | 98.89K | 31.15K | 48.26K | 8.03K | 1.25K |
| Income Before Tax | -8.40M | -10.52M | -9.10M | -6.30M | -4.22M | -3.30M | -16.55M | -1.19M | -687.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -21.24K | -24.02K | -81.90K | -98.89K | -71.62K | -2.10M | 800.00 | -688.56K |
| Net Income | -8.40M | -10.49M | -9.08M | -6.22M | -4.13M | -3.23M | -16.55M | -1.19M | -687.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| EPS Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| Weighted Avg Shares Out | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
| Weighted Avg Shares Out (Dil) | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24
Monopar and NorthStar Amend & Extend Collaboration
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
Monopar Announces CFO Succession
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports